Patents by Inventor Haifeng Tang
Haifeng Tang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220125787Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol APLNR). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition.Type: ApplicationFiled: January 10, 2022Publication date: April 28, 2022Inventors: Haifeng Tang, Michael Hanson, Sarah Boyce, Zhe Nie
-
Patent number: 11230543Abstract: The present invention relates to biaryl monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A1, Q, A2, M, W, RX and Rz are as defined herein. The present invention also relates to compositions which comprise a biaryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.Type: GrantFiled: June 25, 2020Date of Patent: January 25, 2022Assignee: Merck Sharp & Dohme Corp.Inventors: Haifeng Tang, Weiguo Liu, Fa-Xiang Ding, Wanying Sun, Yi Zang, Weidong Pan, Anthony Ogawa, Linda Brockunier, Xianhai Huang, Hongwu Wang, Rudrajit Mal, Tesfaye Biftu, Min Park, Yan Guo, Jinlong Jiang, Helen Y. Chen, Christopher W. Plummer
-
Publication number: 20210346364Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a ?-lactam antibiotic.Type: ApplicationFiled: July 26, 2021Publication date: November 11, 2021Applicant: MERCK SHARP & DOHME CORP.Inventors: John P. CALDWELL, Reynalda DE JESUS, Fa-Xiang DING, Charles J. GIll, Ginny Dai HO, Sookhee N. HA, Sandra J. KOSEOGLU, Marc A. LABROLI, Sang Ho LEE, Christina MADSEN-DUGGAN, Mihir MANDAL, Terry ROEMER, Jing SU, Christopher Michael TAN, Zheng TAN, Haifeng TANG, Hao WANG, Christine YANG, Shu-Wei YANG
-
Patent number: 11141410Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a ?-lactam antibiotic.Type: GrantFiled: December 13, 2016Date of Patent: October 12, 2021Assignee: MERCK SHARP & DOHME CORPInventors: John P. Caldwell, Reynalda De Jesus, Fa-Xiang Ding, Charles J. Gill, Ginny Dai Ho, Sookhee N. Ha, Sandra J. Koseoglu, Marc A. Labroli, Sang Ho Lee, Christina Madsen-Duggan, Mihir Mandal, Terry Roemer, Jing Su, Christopher Michael Tan, Zheng Tan, Haifeng Tang, Hao Wang, Christine Yang, Shu-Wei Yang
-
Patent number: 11109022Abstract: The application relates to a method and a transmitter communication device configured to provide video data to a receiver communication device, wherein the video data comprises one or more groups of frames and each group of frames comprises a plurality of temporally successive frames. The method comprises processing a first frame of a current, i.e. currently processed group of frames using a first modulation and coding scheme of a plurality of modulation and coding schemes and processing a second frame of the current group of frames using a second modulation and coding scheme of the plurality of modulation and coding schemes, and further selecting the second modulation and coding scheme of the plurality of modulation and coding schemes on the basis of a temporal position of the second frame relative to the first frame of the current group of frames.Type: GrantFiled: December 9, 2019Date of Patent: August 31, 2021Assignee: Huawei Technologies Co., Ltd.Inventors: Dimitrios Tsilimantos, Zhijun Chao, Afef Feki, Amaya Nogales Gomez, Xianwen Shi, Haifeng Tang, Stefan Valentin
-
Publication number: 20210053936Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol “APLNR”). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition.Type: ApplicationFiled: February 28, 2019Publication date: February 25, 2021Inventors: Haifeng Tang, Sarah Boyce, Michael Hanson, Zhe Nie
-
Publication number: 20200361928Abstract: The present invention relates to biaryl monobactam compounds of Formula I and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A1, Q, A2, M, W, RX and Rz are as defined herein. The present invention also relates to compositions which comprise a biaryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.Type: ApplicationFiled: June 25, 2020Publication date: November 19, 2020Applicant: Merck Sharp & Dohme Corp.Inventors: Haifeng Tang, Weiguo Liu, Fa-Xiang Ding, Wanying Sun, Yi Zang, Weidong Pan, Anthony Ogawa, Linda Brockunier, Xianhai Huang, Hongwu Wang, Rudrajit Mal, Tesfaye Biftu, Min Park, Yan Guo, Jinlong Jiang, Helen Y. Chen, Christopher W. Plummer
-
Publication number: 20200297702Abstract: The present invention relates to monobactam compounds of Formula (I) and pharmaceutically acceptable salts thereof. The present invention also relates to compositions which comprise a monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.Type: ApplicationFiled: September 27, 2018Publication date: September 24, 2020Applicant: Merck Sharp & Dohme Corp.Inventors: Tesfaye Biftu, Xianhai Huang, Weiguo Liu, Weidong Pan, Min Park, Alexander Pasternak, Wanying Sun, Haifeng Tang, Yi Zang
-
Publication number: 20200261436Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a ?-lactam antibiotic.Type: ApplicationFiled: December 13, 2016Publication date: August 20, 2020Applicant: MERCK SHARP & DOHME CORP.Inventors: John P. CALDWELL, Reynalda DE JESUS, Fa-Xiang DING, Charles J. GIll, Ginny Dai HO, Sookhee N. HA, Sandra J. KOSEOGLU, Marc A. LABROLI, Sang Ho LEE, Christina MADSEN-DUGGAN, Mihir MANDAL, Terry ROEMER, Jing SU, Christopher Michael TAN, Zheng TAN, Haifeng TANG, Hao WANG, Christine YANG, Shu-Wei YANG
-
Publication number: 20200112721Abstract: The application relates to a method and a transmitter communication device configured to provide video data to a receiver communication device, wherein the video data comprises one or more groups of frames and each group of frames comprises a plurality of temporally successive frames. The method comprises processing a first frame of a current, i.e. currently processed group of frames using a first modulation and coding scheme of a plurality of modulation and coding schemes and processing a second frame of the current group of frames using a second modulation and coding scheme of the plurality of modulation and coding schemes, and further selecting the second modulation and coding scheme of the plurality of modulation and coding schemes on the basis of a temporal position of the second frame relative to the first frame of the current group of frames.Type: ApplicationFiled: December 9, 2019Publication date: April 9, 2020Inventors: Dimitrios TSILIMANTOS, Zhijun CHAO, Afef FEKI, Amaya NOGALES GOMEZ, Xianwen SHI, Haifeng TANG, Stefan VALENTIN
-
Patent number: 10513518Abstract: The present invention provides compounds of Formula I (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.Type: GrantFiled: January 25, 2016Date of Patent: December 24, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Reynalda K. deJesus, Qinghong Fu, Jinlong Jiang, Haifeng Tang
-
Patent number: 10407421Abstract: The present invention relates to bicyclic aryl monobactam compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein A1, L, M, W, X, Y, Z, RX and Rz are as defined herein. The present invention also relates to compositions which comprise a bicyclic aryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of one or more beta-lactamase inhibitor compounds.Type: GrantFiled: March 2, 2017Date of Patent: September 10, 2019Assignee: Merck Sharp & Dohme CorpInventors: Weiguo Liu, Fa-Xiang Ding, Wanying Sun, Reynalda Keh Dejesus, Haifeng Tang, Xianhai Huang, Jinlong Jiang, Yan Guo, Hongwu Wang
-
Publication number: 20190071436Abstract: The present invention relates to bicyclic aryl monobactam compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein A1, L, M, W, X, Y, Z, RX and Rz are as defined herein. The present invention also relates to compositions which comprise a bicyclic aryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of one or more beta-lactamase inhibitor compounds.Type: ApplicationFiled: March 2, 2017Publication date: March 7, 2019Applicant: Merck Sharp & Dohme Corp.Inventors: Weiguo Liu, Fa-Xiang Ding, Wanying Sun, Reynalda Keh Dejesus, Haifeng Tang, Xianhai Huang, Jinglong Jiang, Yan Guo, Hongwu Wang
-
Publication number: 20180339983Abstract: The present invention relates to biaryl monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A1, Q, M, W, RX and Rz are as defined herein. The present invention also relates to compositions which comprise a biaryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.Type: ApplicationFiled: December 12, 2016Publication date: November 29, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: Haifeng Tang, Weiguo Liu, Fa-Xiang Ding, Wanying Sun, Yi Zang, Weidong Pan, Anthony Ogawa, Linda Brockunier, Xianhai Huang, Hongwu Wang, Rudrajit Mal, Tesfaye Biftu, Min Park, Yan Guo, Jinlong Jiang, Helen Y. Chen, Christopher W. Plummer
-
Patent number: 9951052Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.Type: GrantFiled: October 27, 2014Date of Patent: April 24, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Alexander Pasternak, Haifeng Tang, Jessica Frie, Ronald Dale Ferguson, Zhiqiang Guo, Zhi-Cai Shi, Brian Cato, Qinghong Fu
-
Publication number: 20180009807Abstract: The present invention provides compounds of Formula I (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.Type: ApplicationFiled: January 25, 2016Publication date: January 11, 2018Inventors: Reynalda K. deJesus, Qinghong Fu, Jinlong Jiang, Haifeng Tang
-
Patent number: 9850245Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.Type: GrantFiled: October 26, 2015Date of Patent: December 26, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Alexander Pasternak, Fa-Xiang Ding, Shuzhi Dong, Jinlong Jiang, Haifeng Tang, Xin Gu, Reynalda K. DeJesus, Jessica Frie, Qinghong Fu, Takao Suzuki, Zhifa Pu
-
Patent number: 9839642Abstract: The present invention relates to compounds of formula I that are metallo-?-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with ?-lactam antibiotics for overcoming resistance.Type: GrantFiled: May 4, 2015Date of Patent: December 12, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Haifeng Tang, Shu-Wei Yang, Mihir Mandal, Jing Su, Guoqing Li, Weidong Pan, Haiqun Tang, Reynalda DeJesus, Jianping Pan, William Hagmann, Fa-Xiang Ding, Li Xiao, Alexander Pasternak, Yuhua Huang, Shuzhi Dong, Dexi Yang
-
Patent number: 9839629Abstract: Novel spirocyclic compounds of formula I: and pharmaceutically acceptable salts thereof are disclosed as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. Pharmaceutical compositions and methods of treatment are also included.Type: GrantFiled: December 19, 2014Date of Patent: December 12, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Shuzhi Dong, Alexander Pasternak, Xin Gu, Qinghong Fu, Jinlong Jiang, Fa-Xiang Ding, Haifeng Tang, Reynalda K. DeJesus, Takao Suzuki
-
Publication number: 20170275292Abstract: The present invention provides compounds of Formula I: (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.Type: ApplicationFiled: October 26, 2015Publication date: September 28, 2017Inventors: Fa-Xiang Ding, Shuzhi Dong, Jinlong Jiang, Haifeng Tang, Reynalda K. DeJesus